SCHEMBL3841282

SCHEMBL3841282

Nc1nc(NC2CCNCC2)ccc1C(=O)c1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.50
CDK1 P06493 3/20 0.50
CDK4 P11802 3/20 0.50
CCND1 P24385 3/20 0.50
HRH3 Q9Y5N1 2/20 0.44
CDK5 Q00535 2/20 0.44
CDK5R1 Q15078 2/20 0.44
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
CCNA2 P20248 1/20 0.40
PAK1 Q13153 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
IRAK4 Q9NWZ3 3/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
TDO2 P48775 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3842619 0.84 CDK1 (0.55) CDK2CDK1CDK4CCND1CYP2C19
SCHEMBL3836156 0.83 CDK1 (0.56) CDK2CDK1CDK4CCND1
SCHEMBL4349160 0.82 CDK1 (0.73) CDK2CDK1CDK4CCND1CDK5
SCHEMBL3837044 0.81 CDK1 (0.59) CDK2CDK1CDK4CCND1CDK5
SCHEMBL3834933 0.81 CDK1 (0.54) CDK2CDK1CDK4CCND1ALDH1A1
SCHEMBL3841254 0.81 CDK2 (0.57) CDK2CDK1CDK4CCND1MAPK8
SCHEMBL3835552 0.80 CDK1 (0.58) CDK2CDK1CDK4CCND1
SCHEMBL3837689 0.80 CDK2 (0.56) CDK2CDK1CDK4CCND1CDK5
SCHEMBL3841223 0.79 CDK1 (0.50) CDK2CDK1CDK4CCND1
SCHEMBL3841297 0.79 CDK1 (0.74) CDK2CDK1CDK4CCND1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1980893-B Novel 2,6-diaminopyridine-3-one derivatives HOFFMANN LA ROCHE 2011-01-19 CN disclosed
EP-1771420-B1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
EP-1771420-B1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
CN-1980893-A Novel 2,6-diaminopyridine-3-one derivatives HOFFMANN LA ROCHE (CH) 2007-06-13 CN disclosed
EP-1771420-A1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-11 EP disclosed
US-20060014708-A1 2,6-Diaminopyridine derivatives BARTKOVITZ DAVID J 2006-01-19 US disclosed
WO-2006005548-A1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014708-A1 2,6-Diaminopyridine derivatives CDK2, CCNA2, CDK6 CDK2 1/4885CDK1 6/4885CDK4 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.